Basic study for establishment of novel antibody therapy for hemophilia A with an antibody enhancing factor VIII activity

尚未报告促进FVIII活性的抗体。在这项研究中，抗FVIII单克隆抗体，mab 216，增强FVIII凝血活性。mab 216剂量依赖性地增加FVIII活性~1.5倍，FXa生成和凝血酶生成分别增加~1.4倍和~2.5倍。鉴定了抗A2表位，并且该抗体增强了Arg 372处的切割。这些发现可能为改善血友病A患者治疗的新原则带来新的曙光。

Antibodies that promote FVIII activity do not appear to have been reported. In this study, anti-FVIII monoclonal antibody, mab216, that enhanced FVIII coagulation activity. The mab216 increased FVIII activity ～1.5-fold dose-dependently, FXa generation and thrombin generation were increased by ～1.4- and ～2.5-fold, respectively. An anti A2 epitope was identified and the antibody enhanced the cleavage at Arg372. The findings may cast new light on new principles for improving the treatment of haemophilia A patients.